# Sensus Healthcare, Inc.: Form 10-Q for the period ended Mar 31, 2022

- Company: [Sensus Healthcare, Inc.](/companies/srts.md) (CIK 1494891)
- Form: 10-Q
- Filed: 2022-05-12
- Accepted by EDGAR: May 12, 2022, 16:23 ET
- Period: 2022-03-31
- Accession: 0001213900-22-025962
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1494891/000121390022025962/f10q0322_sensushealth.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1494891/000121390022025962/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-01 to 2022-03-31 | $10.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-01-01 to 2022-03-31 | $3.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-01-01 to 2022-03-31 | $7.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-01-01 to 2022-03-31 | $728.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-01-01 to 2022-03-31 | $3.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-01-01 to 2022-03-31 | $648.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-01 to 2022-03-31 | $16.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-01-01 to 2022-03-31 | $0.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-01-01 to 2022-03-31 | $0.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-01-01 to 2022-03-31 | 16,641,654 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2022-01-01 to 2022-03-31 | $3.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-01 to 2022-03-31 | $44.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-03-31 | $32.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $48.5m | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $53.9m | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $10.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $11.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-03-31 | $42.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 10,734 characters.

You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”).

### Overview

Sensus is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions.

On February 25, 2022, the Company sold its Sculptura assets for $15 million in cash. Additional information regarding this transaction can be found in Note 2 and in the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 3, 2022.

### Impact of COVID-19

The outbreak of COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has materially and adversely impacted the U.S. and global economies, as well as the Company, and its employees and operations, as well as customer demand. Although we have been able to continue to operate and service customers throughout the pandemic, it significantly impacted the Company’s sales throughout 2020, as social distancing forced physicians to temporarily close their practices. In 2021 and in the first quarter of 2022, as the markets started to open, the Company was able to increase sales significantly. However, the ongoing COVID-19 pandemic, including the possible emergence of new variants, could further impact the Company’s operations and the operations of the Company’s customers, suppliers and vendors as a result of ongoing quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments. The Company cannot reasonably estimate the impact at this time.

### Segment Information

The Company manages its business globally within one reportable segment, which is consistent with how our management reviews the business, prioritizes investment and resource allocation decisions, and assesses operating performance.

### Results of Operations

*(in thousands, except shares and per share data)*

|  | For the Three Months Ended March 31, 2022 | 2021 |
| --- | ---: | ---: |
| **Revenues** | $10,338 | $3,070 |
| **Cost of sales** | 3,189 | 1,484 |
| **Gross profit** | 7,149 | 1,586 |
| **Operating expenses** |  |  |
| Selling and marketing | 1,218 | 1,068 |
| General and administrative | 1,273 | 972 |
| Research and development | 728 | 661 |
| **Total operating expenses** | 3,219 | 2,701 |
| **Income (loss) from operations** | 3,930 | (1,115) |
| **Other income (expense)** |  |  |
| Gain on asset sale | 12,779 | - |
| Interest income | 1 | - |
| **Other income (expense), net** | 12,780 | - |
| **Income (loss) before income tax** | 16,710 | (1,115) |
| Provision for income tax | 648 | - |
| **Net income (loss)** | $16,062 | $(1,115) |

13

### Three months ended March 31, 2022 compared to the three months ended March 31, 2021

**Revenues.** Revenues were $10.3 million for the three months ended March 31, 2022 compared to $3.0 million for the three months ended March 31, 2021, an increase of 236.7% or $7.3 million. The increase was primarily driven by the higher number of units sold in 2022, service revenue on installed units and the impact of COVID-19 in the first three months of 2021.

**Cost of sales.** Cost of sales was $3.2 million for the three months ended March 31, 2022 compared to $1.5 million for the three months ended March 31, 2021, an increase of $1.7 million, or 114.9%. The increase in cost of sales was commensurate with the increase in sales in the three months ended March 31, 2022.

**Gross profit.** Gross profit was $7.1 million for the three months ended March 31, 2022 compared to $1.6 million for the three months ended March 31, 2021, an increase of $5.6 million, or 350.8%. Our overall gross profit percentage was 69.1% in the three months ended March 31, 2022 compared to 51.6% in the corresponding period in 2021. The increase in gross profit was primarily driven by the higher number of units sold in 2022, service revenue on installed units, and the impact of COVID-19 in the first three months of 2021.

**Selling and marketing.** Selling and marketing expense was $1.2 million for the three months ended March 31, 2022 compared to $1.1 million for the three months ended March 31, 2021, an increase of $0.1 million, or 14.0%. The increase was primarily attributable to an increase in tradeshow expense and commissions.

**General and administrative.** General and administrative expense was $1.3 million for the three months ended March 31, 2022 compared to $1.0 million for the three months ended March 31, 2021, an increase of $0.3 million, or 40.0%. The net increase in general and administrative expense was primarily due to professional fees related to the sale of the Sculptura asset and compensation expense.

**Research and development.** Research and development expense was $0.7 million for the three months ended March 31, 2022 and 2021, respectively.

**Other income.** Other income of $12.8 million is related to the gain on the sale of the Sculptura assets.

### Financial Condition

The following discussion summarizes significant changes in assets and liabilities. Please see the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021 contained in Part I, Item 1 of this filing.

### Assets

Cash and cash equivalents at March 31, 2022 increased $18.3 million. See *Cash Flows* for details on the change in cash and cash equivalents during the three months ended March 31, 2022.

Accounts receivable at March 31, 2022 decreased $1.6 million from December 31, 2021, primarily due to collection of receivables offset by an increase in sales of units in the three months ended March 31, 2022.

Inventories at March 31, 2022 increased $566 thousand from December 31, 2021, primarily due to increase in purchases of finished goods offset by shipments of units sold in the three months ended March 31, 2022.

### Liabilities

There were no borrowings under our revolving line of credit at March 31, 2022 or December 31, 2021.

### Liquidity and Capital Resources

The Company’s liquidity position and capital requirements may be impacted by a number of factors, including the following:

- ability to generate and increase revenue;
- fluctuations in gross margins, operating expenses and net results; and
- fluctuations in working capital.

The Company’s primary short-term capital needs, which are subject to change, include expenditures related to:

- expansion of sales and marketing activities; and
- expansion of research and development activities.

Sensus management regularly evaluates cash requirements for current operations, commitments, capital requirements and business development transactions. Given our ability to borrow under our revolving credit facility and other factors, management anticipates that the Company will be able to satisfy its cash requirements for these purposes; however, it may seek to raise additional funds for these or other purposes in the future.

### Cash flows

The following table provides a summary of cash flows for the periods indicated:

*(in thousands)*

| Net cash provided by (used in): | For the Three Months Ended March 31, (unaudited) 2022 | 2021 |
| --- | ---: | ---: |
| Operating activities | $3,082 | $(1,115) |
| Investing activities | 14,956 | (80) |
| Financing activities | 273 | (60) |
| **Total** | $18,311 | $(1,255) |

Net cash provided by operating activities was $3.0 million for the three months ended March 31, 2022, consisting of a net income of $16.1 million, an increase in net operating assets of $0.4 million and non-cash charges of $12.7 million. Cash flows provided by operating activities primarily include the receipt of revenues offset by the payment of operating expenses incurred in the normal course of business. Net cash used in operating activities was $1.1 million for the three months ended March 31, 2021, consisting of a net loss of $1.1 million and a decrease in net operating assets of $0.3 million, partially offset by non-cash charges of $0.3 million. The increase in net operating assets was primarily due to an increase in inventories, prepaid and other current assets and accounts payable and accrued expenses, partially offset by a decrease in accounts receivable, warranties and deferred revenue. Non-cash charges consisted of a gain on asset sale (See Note 2, *Dispositions*, for more information), stock compensation expense, depreciation and amortization, and a warranty provision.

Net cash provided by investing activities for the three months ended March 31, 2020 reflected $15 million of proceeds from the sale of Sculptura assets, partially offset by purchases of property and equipment. Net cash used in investing activities for the three months ended March 31, 2021 reflected $0.1 million of purchases of property and equipment.

Net cash provided in financing activities for the three months ended March 31, 2022 primarily reflected $0.4 million of exercised stock options offset by the repayment of our PPP loan and withholding taxes on stock compensation. Net cash used in financing activities for the three months ended March 31, 2021 primarily reflected $0.1 million of loan repayments and withholding taxes on stock compensation.

### Indebtedness

Please see Note 5, *Debt*, to the financial statements.

### Contractual Obligations and Commitments

Please see Note 8, *Commitments and Contingencies*, to the financial statements.

### Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ significantly from those estimates. For a summary of these and additional accounting policies see Note 1, *Organization and Summary of Significant Accounting Policies,* to the financial statements. In addition, see *Critical Accounting* Policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 1, *Organization and Summary of Significant Accounting Policies*, in the 2021 Annual Report for further information.

## Controls and procedures

As filed, 919 characters.

### Evaluation of Disclosure Control and Procedures

As of March 31, 2022, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of March 31, 2022, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

### Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 561 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2021 Annual Report, as updated in our subsequent quarterly reports. The risks described in our 2021 Annual Report and our subsequent quarterly reports are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.

Filed May 12, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-025962. Last ingested by Listed: Nov 14, 2026, 13:10 ET. No prices; not investment advice.
